Published in J Clin Invest on May 01, 1990
Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci (2006) 1.13
Diseases of the adrenal medulla. Acta Physiol (Oxf) (2007) 0.91
A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer (2001) 0.88
A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer (1999) 0.87
Characterisation of circulating chromogranin A in human cancer patients. Br J Cancer (1996) 0.86
Mass spectrometry identification of granins and other proteins secreted by neuroblastoma cells. Tumour Biol (2013) 0.85
Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients. Biomed Res Int (2013) 0.84
Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One (2015) 0.84
Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers. Oncotarget (2015) 0.78
Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments. J Transl Med (2009) 0.77
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst (1984) 4.01
A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer (1971) 3.71
Purification and properties of an acidic protein from chromaffin granules of bovine adrenal medulla. Biochem J (1967) 2.82
Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet (1971) 2.65
Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature (1967) 2.29
Photometric assay of dopamine- -hydroxylase activity in human blood. Clin Chem (1972) 2.14
Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci U S A (1987) 1.84
Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med (1986) 1.58
Prognostic factor in neuroblastoma. Cancer (1987) 1.47
Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med (1984) 1.14
Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem (1989) 1.10
Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res (1985) 1.06
Mechanism of secretion from the adrenal medulla. I. A microquantitative immunologic assay for bovine adrenal catecholamine storage vesicle protein and its application to studies of the secretory process. Mol Pharmacol (1967) 1.06
A specific soluble protein from the catecholamine storage vesicles of bovine adrenal medulla. I. Purification and chemical characterization. Mol Pharmacol (1967) 1.05
Serum dopamine-beta-hydroxylase activity in neuroblastoma. N Engl J Med (1972) 1.05
Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer (1986) 1.04
Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. Hypertension (1984) 1.02
Changes in human serum dopamine- -hydroxylase activity with age. Nature (1972) 0.98
A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique. J Clin Oncol (1987) 0.98
Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol (1984) 0.97
Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet (1983) 0.96
Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res (1980) 0.93
Homologous radio-immunoassay of human plasma dopamine-beta-hydroxylase: analysis of homospecific activity, circulating plasma pool and intergroup differences based on race, blood pressure and cardiac function. J Hypertens (1983) 0.89
Chromogranin A expression in childhood peripheral neuroectodermal tumors. Prog Clin Biol Res (1988) 0.80
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med (1999) 9.02
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol (1988) 4.35
Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol (1999) 3.35
Synergistic interaction of macrophages and lymphocytes in antigen-induced transformation of lymphocytes. J Exp Med (1970) 3.08
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol (2005) 2.97
Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst (1999) 2.49
Walking speed and stride length predicts 36 months dependency, mortality, and institutionalization in Chinese aged 70 and older. J Am Geriatr Soc (1999) 1.95
Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer (1997) 1.94
Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol (1996) 1.94
Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst (1993) 1.88
Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol (1998) 1.88
Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest (1997) 1.86
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene (1999) 1.79
Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol (2001) 1.76
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol (2000) 1.74
High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest (1991) 1.70
High-risk mild head injury. J Neurosurg (1997) 1.66
Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res (1977) 1.66
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med (1986) 1.58
Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol (2001) 1.58
Identification and characterization of the protein encoded by the human N-myc oncogene. Science (1986) 1.58
Lymphocyte-macrophage interaction in antigen induced in vitro lymphocyte transformation in patients with the Wiskott-Aldrich syndrome and other diseases with anergy. Cell Immunol (1972) 1.56
Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res (1983) 1.53
Genetic influences on endometriosis in an Australian twin sample. sueT@qimr.edu.au. Fertil Steril (1999) 1.51
Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension (2000) 1.50
Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res (1991) 1.48
Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens (1998) 1.48
Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg (1991) 1.47
Residential pesticide exposure and neuroblastoma. Epidemiology (2001) 1.47
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res (1998) 1.45
Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol (1997) 1.44
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol (2000) 1.44
Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem (1984) 1.42
Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol (1995) 1.42
Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med (1991) 1.42
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol (2000) 1.42
Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res (1991) 1.41
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol (2000) 1.40
Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene (1993) 1.38
Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J Biol Chem (1997) 1.38
Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol (1989) 1.36
Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res (1987) 1.31
Amplification units containing human N-myc and c-myc genes. Proc Natl Acad Sci U S A (1986) 1.31
The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer (1997) 1.30
Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sci (1983) 1.30
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol (1998) 1.30
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia (2003) 1.28
Macrophage-bound antigens. I. Induction of delayed hypersensitivity and priming for production of serum antibodies in guinea pigs. J Immunol (1972) 1.26
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol (1982) 1.25
Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides (1998) 1.24
Development and validation of a noninvasive method to determine arterial pressure and vascular compliance. Am J Cardiol (1997) 1.22
Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept (1983) 1.22
Calcium and catecholamine interactions with adrenal chromogranins. Comparison of driving forces in binding and aggregation. J Biol Chem (1992) 1.22
Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res (1998) 1.21
Volumetric and functional heterogeneity of human monocytes. J Clin Invest (1980) 1.19
Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res (1988) 1.18
Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet (1998) 1.16
Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature (1988) 1.15
Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med (1984) 1.14
Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) (1991) 1.14
Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci U S A (1996) 1.14
Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol (2000) 1.14
Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation (1990) 1.14
Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res (2000) 1.13
Molecular genetics of essential hypertension: recent results and emerging strategies. Curr Opin Nephrol Hypertens (2001) 1.13
Chromogranin A. Storage and release in hypertension. Hypertension (1990) 1.12
Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem (1999) 1.12
Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia. Clin Cancer Res (2000) 1.12
Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol (1994) 1.12
Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood (1994) 1.11
Predictors of hysterectomy: an Australian study. Am J Obstet Gynecol (1999) 1.11
N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). Oncogene (1990) 1.10
Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. J Clin Invest (2000) 1.10
Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain (1997) 1.10
Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J Biol Chem (2001) 1.08
Gene amplification in human neuroblastomas: basic mechanisms and clinical implications. Cancer Genet Cytogenet (1986) 1.08
Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res (2001) 1.08
Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood (1994) 1.08
Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest (1996) 1.08
Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol (1993) 1.07
Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res (1985) 1.06
Endocrine cells in the human oxyntic mucosa. A histochemical study. Scand J Gastroenterol (1988) 1.06
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas (1992) 1.05
Cardiovascular haemodynamic response to repeated mental stress in normotensive subjects at genetic risk of hypertension: evidence of enhanced reactivity, blunted adaptation, and delayed recovery. J Hum Hypertens (2003) 1.04
Chromogranin A: posttranslational modifications in secretory granules. Endocrinology (1991) 1.04
Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med (1986) 1.03
Arterial compliance by cuff sphygmomanometer. Application to hypertension and early changes in subjects at genetic risk. Hypertension (1996) 1.03
Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett (1999) 1.03
Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. Cancer Res (1981) 1.02
Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst (1995) 1.02
Plasma chromogranin A. Initial studies in human hypertension. Hypertension (1985) 1.02
Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. Hypertension (1984) 1.02
Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer (1993) 1.02